Bridging data across studies using frequentist and Bayesian estimation.

J Biopharm Stat

b QuintilesIMS , Durham , North Carolina , USA.

Published: January 2018

In drug development programs, an experimental treatment is evaluated across different populations and/or disease types using multiple studies conducted in countries around the world. In order to show the efficacy and safety in a specific population, a bridging study may be required. There are therapeutic areas for which enrolling patients to a trial is very challenging. Therefore, it is of interest to utilize the available historical information from previous studies. However, treatment effect may vary across different subpopulations/disease types; therefore, directly utilizing outcomes from historical studies may result in a biased estimation of treatment effect under investigation in the target trial. In this article, we propose novel approaches using both frequentist and Bayesian frameworks that allow borrowing information from historical studies while accounting for relevant patient's covariates via a propensity-based weighting. We evaluate the operating characteristics of the proposed methods in a simulation study and demonstrate that under certain conditions these methods may lead to improved estimation of a treatment effect.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10543406.2017.1289948DOI Listing

Publication Analysis

Top Keywords

frequentist bayesian
8
historical studies
8
estimation treatment
8
studies
5
bridging data
4
data studies
4
studies frequentist
4
bayesian estimation
4
estimation drug
4
drug development
4

Similar Publications

Animal growth is a fundamental component of population dynamics, which is closely tied to mortality, fecundity, and maturation. As a result, estimating growth often serves as the basis of population assessments. In fish, analysing growth typically involves fitting a growth model to age-at-length data derived from counting growth rings in calcified structures.

View Article and Find Full Text PDF

Drugs associated with tachyphylaxis: results from a retrospective pharmacovigilance study using disproportionality analysis.

Eur J Hosp Pharm

January 2025

Pharmacology & Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain

Background: Tachyphylaxis is the rapid development of drug tolerance following repeated administration.

Objectives: To evaluate the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) data for drugs significantly associated with tachyphylaxis using disproportionality analysis.

Methods: Disproportionality analysis was used for detecting safety signals for identifying drugs associated with tachyphylaxis.

View Article and Find Full Text PDF

A split sample/dual method research protocol is demonstrated to increase transparency while reducing the probability of false discovery. We apply the protocol to examine whether diversity in ownership teams increases or decreases the likelihood of a firm reporting a novel innovation using data from the 2018 United States Census Bureau's Annual Business Survey. Transparency is increased in three ways: 1) all specification testing and identifying potentially productive models is done in an exploratory subsample that 2) preserves the validity of hypothesis test statistics from de novo estimation in the holdout confirmatory sample with 3) all findings publicly documented in an earlier registered report and in this journal publication.

View Article and Find Full Text PDF

Purpose: Patient-Reported Outcomes (PROs) are widely used in clinical trials, epidemiological research, quality of life (QOL) studies, routine clinical care, and medical surveillance. The Patient Reported Outcomes Measurement Information System (PROMIS) is a system of reliable and standardized measures of PROs developed with Item Response Theory (IRT) using latent scores. Power estimation is critical to clinical trials and research designs.

View Article and Find Full Text PDF

Transcutaneous auricular vagus nerve stimulation (taVNS) has been tested as a strategy to facilitate fear extinction learning based on the hypothesis that taVNS increases central noradrenergic activity. Four studies out of six found taVNS to enhance extinction learning especially at the beginning of extinction. Facilitatory effects of taVNS were mainly observed in US expectancy, less in fear-potentiated startle (FPS), and not in the skin conductance response (SCR).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!